ABSTRACT
Introduction The recent severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic had a devasting global impact. Many people suffered from coronavirus disease 2019 (COVID-19) and some experienced persistent symptoms interrupting their lives even further. The World Health Organization (WHO) defined the condition of these persistent symptoms as post-COVID-19 condition (PCC). The most prevalent PCC symptoms are fatigue, dyspnea, sleep disturbances, coughing, anosmia and ageusia, chest pain, and headaches. This article describes the protocol of the Basel Long COVID Cohort Study (BALCoS), which aims at fostering understanding of PCC and investigating underlying mechanisms for the development and course of the condition by focusing on participants’ health status and symptoms with repeated measures over one year.
Methods and analysis BALCoS is a prospective single site cohort study. Inclusion criteria are a confirmed PCC diagnosis according to WHO or a subjective attribution of persistent symptoms to PCC, proficiency in German to follow study procedures, and at least 18 years of age. It comprises blood sample collections, standardized neurocognitive and psychometric tests, physical performance measures, and ecological momentary assessments (EMAs). Standardized tests and EMAs are administered at baseline (BL), and at 3-, 6-, and 12-months follow-up. At BL and 12-month follow-up, physical performance and neurocognitive abilities are assessed. Participants provide blood samples at BL. The study is exploratory in nature and a sample size of at least 120 participants is targeted. The study is part of a larger Horizon Europe Long COVID project combining mechanistic, clinical, and intervention studies within an interdisciplinary European research consortium.
Ethics and dissemination The Ethics Commission of Northwest and Central Switzerland approved the study (BASEC-ID: 2023-00359), which is registered at ClinicalTrial.gov (ID: NCT05781893). All participants provide written informed consent. Key results from the study will be published in peer-reviewed journals.
Funding Details BALCoS is primarily funded by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 22.00094 in the context of the European Union’s Horizon Europe research and innovation program under grant agreement No. 101057553.
Competing Interest Statement
Conflict of Interest Statement GM received funding from the Stanley Thomas Johnson Stiftung & Gottfried und Julia–Bangerter–Rhyner–Stiftung under projects no. PC 28/17 and PC 05/18, from Health Promotion Switzerland under project no. 18.191/K50001, from the Swiss Heart Foundation under project no. FF21101, from the Research Foundation of the International Psychoanalytic University (IPU) Berlin under projects no. 5087 and 5217, from the Swiss National Science Foundation (SNSF) under project no. 100014_135328, from the German Federal Ministry of Education and Research under budget item 68606, from the Hasler Foundation under project No. 23004, from SERI under contract number 22.00094 in the context of a European Union (Horizon Europe) research consortium “Long COVID” (funding number: 101057553) and from Wings Health in the context of a proof–of–concept study. GM is a cofounder and shareholder of Therayou AG, active in digital and blended mental healthcare. GM receives royalties from publishing companies as author, including a book published by Springer, and an honorarium from Lundbeck for speaking at a symposium. Furthermore, GM is compensated for providing psychotherapy to patients, acting as a supervisor, serving as a self–experience facilitator (“Selbsterfahrungsleiter”), and for postgraduate training of psychotherapists, psychosomatic specialists, and supervisors. RaS received funding from Promotion Sante Suisse (Gesundheitsförderung Schweiz) under contract no. 18.191/ K50001, from the Health Department Basel–City, from SERI under contract number 22.00094 in the context of a European Union (Horizon Europe) research consortium “Long COVID” (funding number: 101057553), and from Wings Health in the context of a proof–of–concept study. RaS is co–editor of the German AWMF S3–Guidelines on Functional Complaints and contributed to the German guidelines on irritable bowel syndrome, and on Lyme Borreliosis. RaS is chairman of the Basel Institute for Psychosomatic Medicine (BIPM), and founder and managing director of the Psychosomatic and Psychosocial Services GmbH, that develops and implements psychosomatic and psychosocial training and continuing education programs. RaS is member of the Swiss Academy of Psychosomatic and Psychosocial Medicine (SAPPM) – where he is member of the Scientific Advisory Board, of the Société Médicale Suisse d′Hypnose (SMSH), of the Dt. Kollegium für Psychosomatische Medizin (DKPM), of the Dt. Gesellschaft für Psychosomatische Medizin und Ärztliche Psychotherapie (DGPM), and of the German Balint Society (DBG). RaS serves as spokesman of DKPM and DGPM for Consultation and Liaison Psychosomatics. He is a member of the board of trustees of the Foundation Psychosomatic and Social Medicine (Ascona Foundation). MM served as a consultant for AstraZeneca, Böhringer Ingelheim, Bayer and received unrestricted grants from Menarini, AstraZeneca, Bayer, Bristol–Myers Squibb Pfizer, Daiichi Sankyo, GlaxoSmithKline, IBSA, Lilly, MSD, Novo Nordisk, Sanofi–Aventis, and Viatris. ReS received funding from SERI under contract number 22.00094 in the context of a European Union (Horizon Europe) research consortium “Long COVID” (funding number: 101057553). AM received unrestricted grants from Menarini, AstraZeneca, Bayer, Bristol–Myers Squibb Pfizer, Daiichi Sankyo, GlaxoSmithKline, IBSA, Lilly, MSD, Novo Nordisk, Sanofi–Aventis, and Viatris.
Funding Statement
Funding Details BALCoS is primarily funded by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 22.00094 in the context of the European Unions Horizon Europe research and innovation program under grant agreement No. 101057553.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study has been approved by the Department of Clinical Research at University Hospital Basel (ID: th22schaefert), the Ethics Commission of Northwest and Central Switzerland (ID: 2023-00359) and is registered at ClinicalTrial.gov (ID: NCT05781893).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* shared first authorship
↵♦ shared last authorship
Sponsors: Prof. Dr. med. Rainer Schaefert, PD Dr. med. Michael Mayr
Principle Investigator: Prof. Dr. Gunther Meinlschmidt, gunther.meinlschmidt{at}unibas.ch
Co-Investigators: Dr. rer. nat. Rebekka Schnepper, Dr. med. Andrea Meienberg, Dr. med. Katrin Bopp
Submitting Author: Stefan Rohner, stefan.rohner{at}usb.ch
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.